Translating Novel & Safe Transformative Dry AMD Drugs
Into the Clinic
Revolutionizing Earlier Intervention & Reduced Administration Frequency of More Efficacious & Safer Dry AMD & GA Drugs
The surge of ground-breaking updates in Geographic Atrophy, along with significant advancements in developing robust biomarkers and functional endpoints, has ignited a wave of innovation in the field of ophthalmic drug development.
The 5th Dry AMD & GA Therapeutics Summit will unite 80+ biopharma stakeholders, from discovery to early clinical development, across three days of focused discussion. This summit is the definitive forum for KOLs, industry experts, and regulators to drive the next generation of dry AMD and Geographic Atrophy therapeutics forward.
Join us to explore the latest in preclinical models, optimize trial strategies, and overcome safety and regulatory challenges to supercharge your pipeline
Featuring 19+ World-Class Speakers:
Cynthia Tung
Clinical Program Leader (Medical Director), Ophthalmology, Early Clinical Development
Boehringer Ingelheim
Previous Attendees Include:
Download the 2024 Event Guide for More Information On:
- 19+ Expert Speaker Faculty
- Interactive Workshops
- Full access to the 3-day agenda and scientific content breakdown
- and more!
Hear What Your Peers Had to Say:
“The meeting provided a comprehensive picture of the current GA treatment landscape. The small meeting format gave audience opportunities to closely interact with the speaker”
Executive Director, Clinical Development, Ophthalmology, AbbVie
“Excellent knowledgeable speakers, interactive, wide range of industry from start-ups to strategies, discussion of challenges not just successes including regulatory perspectives. The basic scientists and clinicians added great flavor”
Associate Director, Ophthalmology, Dompe International
Other Events in the Series:
